Abstract
Multiple myeloma (MM) is a challenging hematological cancer which typically grows in bone marrow. MM accounts for 10% of hematological malignancies and 1.8% of cancers. The recent treatment strategies have significantly improved progression-free survival for MM patients in the last decade; however, a relapse for most MM patients is inevitable. In this review we discuss current treatment, important pathways for proliferation, survival, immune suppression, and resistance that could be targeted for future treatments.
| Original language | English (US) |
|---|---|
| Article number | 415 |
| Journal | Pharmaceuticals |
| Volume | 16 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2023 |
All Science Journal Classification (ASJC) codes
- Molecular Medicine
- Pharmaceutical Science
- Drug Discovery
Fingerprint
Dive into the research topics of 'Past, Present, and a Glance into the Future of Multiple Myeloma Treatment'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver